TN2009000511A1 - Sulfonyl-quinoline derivatives - Google Patents

Sulfonyl-quinoline derivatives

Info

Publication number
TN2009000511A1
TN2009000511A1 TNP2009000511A TN2009000511A TN2009000511A1 TN 2009000511 A1 TN2009000511 A1 TN 2009000511A1 TN P2009000511 A TNP2009000511 A TN P2009000511A TN 2009000511 A TN2009000511 A TN 2009000511A TN 2009000511 A1 TN2009000511 A1 TN 2009000511A1
Authority
TN
Tunisia
Prior art keywords
heteroaryl group
optionally substituted
mglurl
substituted phenyl
sulfonyl
Prior art date
Application number
TNP2009000511A
Other languages
English (en)
Inventor
Janos Galambos
Gyorgy Keseru
Krisztina Gal
Amrita Agnes Bobok
Csaba Weber
Inolya Prauda
Gabor Andras Wagner
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0700417A external-priority patent/HU0700417D0/hu
Priority claimed from HU0800376A external-priority patent/HUP0800376A2/hu
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of TN2009000511A1 publication Critical patent/TN2009000511A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
TNP2009000511A 2007-06-18 2009-12-09 Sulfonyl-quinoline derivatives TN2009000511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0700417A HU0700417D0 (en) 2007-06-18 2007-06-18 Sulfonyl-quinoline derivatives
HU0800376A HUP0800376A2 (en) 2008-06-12 2008-06-12 Sulfonyl-quinoline derivatives
PCT/HU2008/000068 WO2008155588A1 (fr) 2007-06-18 2008-06-17 Dérivés de la sulfonyle quinoléine

Publications (1)

Publication Number Publication Date
TN2009000511A1 true TN2009000511A1 (en) 2011-03-31

Family

ID=89988338

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000511A TN2009000511A1 (en) 2007-06-18 2009-12-09 Sulfonyl-quinoline derivatives

Country Status (27)

Country Link
EP (1) EP2167469B1 (fr)
JP (1) JP5543917B2 (fr)
KR (1) KR101532101B1 (fr)
CN (1) CN101730684B (fr)
AU (1) AU2008264999B8 (fr)
BR (1) BRPI0812816B8 (fr)
CA (1) CA2690079C (fr)
CO (1) CO6311082A2 (fr)
CU (1) CU23822A3 (fr)
CY (1) CY1113251T1 (fr)
DK (1) DK2167469T3 (fr)
EA (1) EA016691B1 (fr)
EC (1) ECSP109884A (fr)
ES (1) ES2392905T3 (fr)
GE (1) GEP20125524B (fr)
HR (1) HRP20120877T1 (fr)
IL (1) IL202463A (fr)
MX (1) MX2009013959A (fr)
MY (1) MY146992A (fr)
NI (1) NI200900217A (fr)
NZ (1) NZ581853A (fr)
PL (1) PL2167469T3 (fr)
PT (1) PT2167469E (fr)
RS (1) RS52495B (fr)
SI (1) SI2167469T1 (fr)
TN (1) TN2009000511A1 (fr)
WO (1) WO2008155588A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009307825A1 (en) * 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
MX344308B (es) * 2011-11-03 2016-12-13 Merck Sharp & Dohme Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US9932310B2 (en) * 2016-02-08 2018-04-03 City Of Hope DNA2 inhibitors for cancer treatment
KR101893515B1 (ko) * 2017-06-09 2018-08-30 영남대학교 산학협력단 구리 촉매를 이용한 4-하이드록시-3-설파닐쿠마린 유도체 또는 4-하이드록시-3-설파닐퀴놀리논 유도체의 신규 제조방법 및 이로 제조된 유도체 화합물과 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058313A1 (fr) * 1999-03-29 2000-10-05 Neurogen Corporation Derives de quinoline 4-substitues en tant que ligands des recepteurs de gaba
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
SI1497266T1 (sl) * 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
CA2537141A1 (fr) * 2003-09-02 2005-03-10 Merck And Co., Inc. Amines et ethers de bipyridyle utilises comme modulateurs du recepteur 5 metabotropique au glutamate
PE20050676A1 (es) * 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
ATE444069T1 (de) * 2005-12-20 2009-10-15 Richter Gedeon Nyrt Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen

Also Published As

Publication number Publication date
CO6311082A2 (es) 2011-08-22
EA016691B1 (ru) 2012-06-29
CA2690079A1 (fr) 2008-12-24
ECSP109884A (es) 2010-02-26
CY1113251T1 (el) 2016-04-13
KR101532101B1 (ko) 2015-06-26
AU2008264999B2 (en) 2013-09-26
EP2167469A1 (fr) 2010-03-31
MY146992A (en) 2012-10-15
CN101730684A (zh) 2010-06-09
BRPI0812816B8 (pt) 2021-05-25
NI200900217A (es) 2010-10-04
NZ581853A (en) 2012-11-30
WO2008155588A1 (fr) 2008-12-24
CU20090219A7 (es) 2011-10-14
GEP20125524B (en) 2012-05-25
AU2008264999B8 (en) 2013-10-31
IL202463A (en) 2013-08-29
PL2167469T3 (pl) 2013-01-31
WO2008155588A8 (fr) 2009-12-30
EA201070025A1 (ru) 2010-04-30
CN101730684B (zh) 2013-07-24
CU23822A3 (es) 2012-06-21
BRPI0812816A2 (pt) 2014-12-23
RS52495B (sr) 2013-02-28
MX2009013959A (es) 2010-03-09
CA2690079C (fr) 2016-01-26
JP5543917B2 (ja) 2014-07-09
PT2167469E (pt) 2012-11-20
HK1141009A1 (en) 2010-10-29
ES2392905T3 (es) 2012-12-14
AU2008264999A1 (en) 2008-12-24
BRPI0812816B1 (pt) 2020-09-15
EP2167469B1 (fr) 2012-08-15
HRP20120877T1 (hr) 2012-11-30
SI2167469T1 (sl) 2012-10-30
JP2010530407A (ja) 2010-09-09
DK2167469T3 (da) 2012-11-12
IL202463A0 (en) 2010-06-30
KR20100021434A (ko) 2010-02-24

Similar Documents

Publication Publication Date Title
MY203060A (en) Prophylactic or therapeutic agent for spinal muscular atrophy
EA201170096A1 (ru) Замещенные производные пиримидона
MX2009013959A (es) Derivados de sulfonil-quinolina.
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
NO20063452L (no) Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler
EP2597088A4 (fr) Antagoniste des récepteurs p2x4
NO20064008L (no) Forbindelser
TN2009000342A1 (en) Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
MX2009010909A (es) Derivados de ftalazino y su uso como medicamento para tratar el cancer.
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
MY139887A (en) Tetrahydronaphthyridine derivatives and a process for preparing the same.
PH12013501572A1 (en) 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
HRP20110785T8 (en) Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands
CR11578A (es) Derivados de oxadiazol activos e 1-fosfato de esfingosina
TNSN08161A1 (en) 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
EA200801536A1 (ru) Новые тиенопирсульфоновые производные
TW200609223A (en) Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives
ATE396183T1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
HRP20110780T1 (hr) Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6